Current chemotherapy research status and consideration of early-stage epithelial ovarian cancer

Abstract

Ovarian cancer is one of the most deadly malignancies of female reproductive system, with complex pathological types. The epithelial ovarian cancer (EOC) is the most common pathological type in ovarian cancer, but early-stage epithelial ovarian cancer (EEOC) only accounts for 30% in all diagnosed ovarian cancer. Adjuvant chemotherapy is the standard treatment strategy for high-risk EEOC patients after comprehensive staging surgery, but many issues are still worthy of discussion in adjuvant chemotherapy. We intend to clarify the current research status of postoperative adjuvant chemotherapy in patients with EEOC, such as the benefits of chemotherapy, the choice of chemotherapy regimen and the best timing for chemotherapy, the duration of chemotherapy and lymphadenectomy. We expect that this review can help providing references for standardized treatment of this disease. Key words: Ovarian neoplasms; Epithelioid cells; Carcinoma, endometrioid; Epithelial ovarian neoplasms, early stage; Adenocarcinoma, clear cell; Antineoplastic combined chemotherapy protocols; Female